Citations

Clear

3138 citation(s) found for "Smith, AM".

IC‐P‐068: Regional and whole‐brain atrophy rates in autopsy‐confirmed dementia with Lewy bodies and Alzheimer's disease
Weigand, Stephen D. , Przybelski, Scott A. , Gunter, Jeffrey L. , Wille, Samantha, Murray, Melissa E. , Petersen, Ronald C. , Parisi, Joseph E. , Nedelská, Zuzana , Ferman, Tanis J. , Boeve, Bradley F. , Smith, Glenn E. , Geda, Yonas E. , Knopman, David S. , Jack, Clifford R. , Dickson, Dennis W. , Kantarci, Kejal , Murray, Melissa E

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2013.05.065 Get It

P4–086: Dramatic improvement with donepezil in a case of dementia with Lewy bodies
Allen, Laura A., Josephs, Keith A. , Ivnik, Robert J., Lowe, Val J. , Pittock, Sean J. , Smith, Glenn E. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_18 | Pages: No page available

10.1016/j.jalz.2013.05.1475 Get It

IC‐P‐060: MRS differentiates MCI patients who progress to dementia with Lewy bodies and Alzheimer's disease
Zhang, Bing , Maroney‐Smith, Mandie, Petersen, Ronald C. , Ferman, Tanis J. , Boeve, Bradley F. , Smith, Glenn E. , Knopman, David S. , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2013.05.056 Get It

A Polymeric Fastener Can Easily Functionalize Liposome Surfaces with Gadolinium for Enhanced Magnetic Resonance Imaging
Smith, Cartney E., Shkumatov, Artem, Withers, Sarah G., Yang, Binxia , Glockner, James F., Roy, Edward J. , Wong, Chun‐Ho , Zimmerman, Steven C. , Kong, Hyunjoon , Misra, Sanjay , Misra, Sanjay , Kong, Hyunjoon , Misra, Sanjay

Mayo Clinic

ACS Nano | October 1, 2013 | Volume: 7 | Issue: 11 | Pages: 9599-9610

10.1021/nn4026228 | PMID 24083377 Get It

Utility of multimodal analgesia with fascia iliaca blockade for acute pain management following hip arthroscopy
Krych, Aaron J. , Baran, Sean, Kuzma, Scott A., Smith, Hugh M. , Levy, Bruce A. , Johnson, Rebecca L. , Krych, Aaron J

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | September 23, 2013 | Volume: 22 | Issue: 4 | Pages: 843-847

10.1007/s00167-013-2665-y | PMID 24061718 Get It

AbstractPurposeThe purpose of this study was to evaluate the utility of multimodal analgesia with fascia iliaca blockade and for acute pain control in patients undergoing hip arthroscopy.MethodsThirty consecutive patients undergoing primary hip arthroscopy were prospectively studied. All patients were treated preoperatively with ultrasound‐guided single injection fascia iliaca blockade and multimodal analgesia. Data collected included post‐operative nausea, numeric rating scale (NRS) pain scores during rest and activity, opioid consumption during the first five days (recorded as tablets of 5 mg hydrocodone/500 mg acetaminophen) and overall patient satisfaction with analgesia.ResultsThis study included 23 female and 7 male patients with a median age of 35 years (range 14–58). No patient required medication for post‐operative nausea. The overall NRS scores were an average of 3.9 on day 0, 3.6 on day 1, 3.4 on day 2, 2.9 on day 3, 3.0 on day 4 and 2.7 on day 5. The average tablets of opioid taken were 1.5 on day 0, 1.2 on day 1, 1.3 on day 2, 1.0 on day 3, 1.1 on day 4 and 0.9 on day 5. Overall, 20 patients rated their post‐operative pain control as very satisfied (67 %), and 10 patients as satisfied (33 %). There were no complications or side effects from the fascia iliaca blockade.ConclusionIn this prospective study, multimodal analgesia with fascia iliaca blockade following hip arthroscopy was safe and effective. The quality of early post‐operative analgesia provided by the fascia iliaca blockade was excellent and resulted in low opioid consumption, high quality of pain relief and high overall patient satisfaction.Level of evidenceProspective case series, Level II.
Insulin pumps with a sensor and threshold-suspend reduced nocturnal hypoglycemia in type 1 diabetes
Smith, Steven C. , McCoy, Rozalina G.

Mayo Clinic

Annals of Internal Medicine | September 16, 2013 | Volume: 159 | Issue: 6 | Pages: JC7

10.7326/0003-4819-159-6-201309170-02007 | PMID 24042390 Get It

Ultrasound‐guided Ischial Bursa Injection: Technique and Positioning Considerations
Wisniewski, Steve J. , Hurdle, Mark Friedrich B., Erickson, Jason M., Smith, Jay , Hurdle, Mark, Finnoff, Jonathan T.

Mayo Clinic

PM&R | August 31, 2013 | Volume: 6 | Issue: 1 | Pages: 56-60

10.1016/j.pmrj.2013.08.603 | PMID 24001885 Get It

ObjectivesTo 1) describe and validate an ultrasound‐guided ischial bursa injection technique in an unembalmed cadaveric model and 2) to compare the distance between the ischial tuberosity and the sciatic nerve in a hip neutral versus 90° flexed hip position in asymptomatic volunteers.DesignThe first part was a single‐blind prospective study. The second part was a prospective cohort study.SettingAn academic institution procedural skills laboratory and outpatient clinic.ParticipantsThe first part of the study involved 1 cadaveric specimen. The second part of the study involved 20 asymptomatic subjects. The mean age of the subjects was 28 years, and the mean (standard deviation) body mass index was 23.2 ± 2.8 kg/m2 (minimum, 18.3 kg/m2; maximum, 29.5 kg/m2).MethodsIn the first part of the study, a single operator completed bilateral ultrasound‐guided ischial bursa injections in an unembalmed cadaveric specimen by using diluted colored latex. In the second part of the study, ultrasound was used in 20 asymptomatic volunteer subjects (10 men and 10 women) to measure the distance from the lateral edge of the ischial tuberosity to the sciatic nerve.Main Outcome MeasurementsThe injections were graded for accuracy as follows: accurate (all injectate contained within the ischial bursa), accurate with overflow (injectate within the ischial bursa but also located in adjacent structures other than the needle track), or inaccurate (injectate not within the ischial bursa). The second part of the study measured the distance from the ischial tuberosity to the sciatic nerve with subjects in 2 different positions (prone and side lying with the tested hip flexed to 90°).ResultsPostinjection cadaveric dissections revealed that both ultrasound‐guided injections accurately placed liquid latex within the ischial bursae. There was no evidence of injury to surrounding neurovascular structures. Among asymptomatic volunteers, the average distance between the ischial tuberosity and the sciatic nerve increased from 28.4 mm (range, 20.5‐38.9 mm) in the neutral position to 41.9 mm (range, 30.9‐66.0 mm) with the hip flexed to 90° (average change, 13.5 mm away from the ischial tuberosity; P = .0001).ConclusionsUltrasound‐guided ischial bursa injections are technically feasible. Flexing the hip to 90° increases the distance between the ischial tuberosity and the sciatic nerve in asymptomatic volunteers, thus potentially resulting in a safer needle trajectory when ischial bursa injections are clinically indicated. Further investigation in clinical settings is warranted to validate these findings.
Small orangiophilic squamous‐like cells: An underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology
Calderó, Sònia Gatius, Gmitro, Stephen, Petris, Giovanni De , Zarka, Mathew A., Chen, Longwen , Smith, Maxwell L.

Mayo Clinic

Cancer Cytopathology | August 26, 2013 | Volume: 122 | Issue: 1 | Pages: 70-75

10.1002/cncy.21345 | PMID 23983174 Get It

BACKGROUNDThe cytological diagnosis of malignant mesothelioma (MM) on serous effusion is challenging due to significant morphologic overlap with reactive mesothelial cells and adenocarcinoma. One of the morphologic features of MM in effusion cytology, small orangiophilic squamous‐like cells (SOSLC), has received little attention. To the best of the authors' knowledge, the current study is the first to assess the sensitivity and specificity of SOSLC in serous effusion specimens from histology‐proven MM cases along with those of reactive mesothelial and adenocarcinoma cases.METHODSA total of 130 cases of pleural (86 cases) and peritoneal (44 cases) effusion cytology cases (30 with histology‐proven MM, 41 with adenocarcinoma, and 59 with reactive mesothelial cells) were studied. The presence or absence of SOSLC was recorded in each case.RESULTSThe cytological diagnoses of the 30 histology‐proven MM cases included 1) atypical mesothelial cells, favor reactive (4 cases); 2) atypical mesothelial cells, suspicious for or cannot exclude mesothelioma (18 cases); and 3) positive for MM (8 cases). SOSLC were found in 10 of the 30 MM effusion cases (33.3%), 1 of the 41 adenocarcinoma cases (2.4%), and 5 of the 59 reactive mesothelial cell cases (8.5%). SOSLC were more likely to be present in MM effusions compared with either adenocarcinoma (P < .0001) or reactive mesothelial cell (P < .02) effusions. All 10 cases of MM with SOSLC were from pleural fluids. One case of peritoneal serous adenocarcinoma had SOSLC and 5 cases of reactive mesothelial cells in peritoneal fluid were found to have SOSLC.CONCLUSIONSAlthough not sensitive, the presence of SOSLC is quite specific for MM in pleural fluid cytology specimens. Finding this morphological feature in pleural fluid should alert the pathologist to a possible diagnosis of MM.Cancer (Cancer Cytopathol) 2014;122:70–75. © 2013 American Cancer Society.
Delayed allograft inflammation following alemtuzumab induction for kidney transplantation
Heilman, Raymond L. , Khamash, Hasan , Chakkera, Harini A. , Moss, Adyr A. , Reddy, Kunam S. , Smith, Maxwell L. , Chakkera, Harini A

Mayo Clinic

Clinical Transplantation | August 8, 2013 | Volume: 27 | Issue: 5 | Pages: 772-780

10.1111/ctr.12201 | PMID 23924146 Get It

AbstractBackgroundIn a recent clinical trial in kidney transplant recipients, induction with alemtuzumab and rabbit‐antithymocyte globulin (r‐ATG) was equally effective in preventing rejection during the first post‐transplant year; however, this study did not include protocol biopsies.MethodsThe aim of this study was to analyze the impact of alemtuzumab induction on rejection and subclinical inflammation during the first post‐transplant year compared with a historic control group receiving induction with r‐ATG. All patients received tacrolimus and mycophenolate mofetil (MMF).ResultsThere were 361 in the alemtuzumab group and 478 in the r‐ATG groups. Rejection (excluding Banff borderline), during the first year, occurred in 14% of the alemtuzumab group and 9% of the r‐ATG group (p = 0.03). Estimated glomerular filtration rate (GFR) (chronic kidney disease (CKD)‐EPI formula) at one yr and graft survival at three yr were similar. On the protocol biopsies, interstitial inflammation (Banff i scores) and tubulitis (Banff t scores) were more likely in the r‐ATG group at one month, but at four and 12 months, both inflammation and tubulitis were more likely in the alemtuzumab group.ConclusionsWe conclude that alemtuzumab induction is associated with delayed inflammation at four and 12 months, but this inflammation did not appear to negatively impact the GFR or graft survival.